ClinicalTrials.gg
CompletedNCT02959619Updated Aug 21, 2023

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

A Phase 1 interventional study of Ensartinib in Solid Tumor and Non-Small Cell Lung Cancer Metastatic, sponsored by Betta Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 14 under way, 2 of them phase 3. ensartinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 20
48 · median 48
Started
2017
with 2 others
Phase 1
2 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
4 of 20
Betta Pharmaceuticals Co., Ltd.

Among the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About ensartinib

ensartinib: first FDA approval 2024 (ENSACOVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer

Read the detailed description

The initial purpose of the study is to determine the largest amount of ensartinib that can be safely given to humans. An expansion phase will be conducted to assess the preliminary anti-tumor activity in ALK-positive non-small cell lung cancer once the recommended Phase 2 dose has been established.

03

Conditions studied

  • Solid Tumor
  • Non-Small Cell Lung Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced solid tumor
  • For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations positive by FISH or IHC
  • Eastern Cooperative Group ) Performance Status score of 0 or 1
  • Adequate organ system function
  • Male patients willing to use adequate measures; female patients who are not of , and female patients of child-bearing potential who agree to use adequate contraceptive measures
  • per
  • Willingness and ability to comply with the trial and follow-up procedures
  • Written informed consents are required to indicate that the patients are aware of the nature of the study

Exclusion criteria

Exclusion Criteria:

  • Current use of anticancer therapy.
  • Use of an drug within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of ensartinib
  • Any major surgery, radiotherapy, or immunotherapy within the last 21 days.
  • Chemotherapy regimens with delayed toxicity within the last 4 weeks.
  • Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.
  • Prior stem cell transplant
  • Patients with a known allergy or delayed reaction to drugs chemically related to ensartinib or to the active ingredient of ensartinib
  • Prior use of ALK TKIs with the exception of crizotinib
  • Primary CNS tumors or meningeal
  • Pregnant or breastfeeding female
  • Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of ensartinib
  • cardiovascular disease.
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
  • Concurrent condition evaluated by investigator would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled
  • Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Ensartinib

    Escalating dose of ensartinib was orally given once er day

    Drug: Ensartinib

Interventions

  • Oral ensartinib was given daily at escalating doses in a 28-day cycle

    Also known as: X-396

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    Time frame: 12 months

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    To characterize the preliminary pharmacokinetics of single-agent ensartinib

    Time frame: 12 months

  2. Area under the plasma concentration versus time curve (AUC)

    To characterize the preliminary pharmacokinetics of single-agent ensartinib

    Time frame: 12 months

  3. Half-life time

    To characterize the preliminary pharmacokinetics of single-agent ensartinib

    Time frame: 12 months

07

Study locations

1 site
  • Sun yat-sen Univerisity Cancer Center
    Guanzhou, Guangdong 510060, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Oct 2019, 31 months.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 31 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2016
First posted
Nov 9, 2016
StartActual
Mar 6, 2017
Primary completionActual
Oct 31, 2019
CompletionActual
Apr 23, 2020
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02959619
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Mar 6, 2017
Primary completion
Oct 31, 2019
Completion
Apr 23, 2020
Last update
Aug 21, 2023

Study contacts

Li Zhang, MD
study chair · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion